Classification of patient characteristics associated with reported adverse drug events to neuraminidase inhibitors: an applicability study of latent class analysis in pharmacovigilance

Kubota K(2001)Signal detection from spontaneous reports: new methods from UK MCA, US FDA and WHO Pharmacoepidemiology 6 101-108

Miwa S(2009)Introduction to latent class models Theory Methods 24 345-356

Kamiya S(2018)A study of the population background of adverse events of common cold drugs using the PMDA adverse drug event reporting database Jpn J Pharmacoepidemiol Ekigaku 23 75-87

Yamauchi K(2017)Identification of a syndrome class of neuropsychiatric adverse reactions to mefloquine from latent class modeling of FDA adverse event reporting system data Drugs R D 17 199-210

Watanabe M(2017)Current safety concerns with human papillomavirus vaccine: a cluster analysis of reports in VigiBase® Drug Saf 40 81-90

Nevin RL(2013)Neuropsychiatric adverse effects of oseltamivir in the FDA adverse event reporting system, 1999–2012 BMJ 347 f4656-95

Leoutsakos JM(2011)A pharmacoepidemiological study of the relationship between neuropsychiatric symptoms and therapeutic drugs after influenza Pharmacoepidemiology 15 73-621

Chandler RE(2009)Oseltamivir and abnormal behaviours: true or not ? Epidemiology 20 619-1313

Juhlin K(2009)Possible harms of oseltamivir—a call for urgent action Lancet 374 1312-68

Fransson J(2012)An econometric approach using latent class analysis Ann Rep Hum Sci 33 43-16S

Kubota K(2001)Signal detection from spontaneous reports: new methods from UK MCA, US FDA and WHO Pharmacoepidemiology 6 101-108

Miwa S(2009)Introduction to latent class models Theory Methods 24 345-356

Kamiya S(2018)A study of the population background of adverse events of common cold drugs using the PMDA adverse drug event reporting database Jpn J Pharmacoepidemiol Ekigaku 23 75-87

Yamauchi K(2017)Identification of a syndrome class of neuropsychiatric adverse reactions to mefloquine from latent class modeling of FDA adverse event reporting system data Drugs R D 17 199-210

Watanabe M(2017)Current safety concerns with human papillomavirus vaccine: a cluster analysis of reports in VigiBase® Drug Saf 40 81-90

Nevin RL(2013)Neuropsychiatric adverse effects of oseltamivir in the FDA adverse event reporting system, 1999–2012 BMJ 347 f4656-95

Leoutsakos JM(2011)A pharmacoepidemiological study of the relationship between neuropsychiatric symptoms and therapeutic drugs after influenza Pharmacoepidemiology 15 73-621

Chandler RE(2009)Oseltamivir and abnormal behaviours: true or not ? Epidemiology 20 619-1313

Juhlin K(2009)Possible harms of oseltamivir—a call for urgent action Lancet 374 1312-68

Fransson J(2012)An econometric approach using latent class analysis Ann Rep Hum Sci 33 43-16S